TY  - JOUR

T1  - Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying antirheumatic drugs: a NICE single technology appraisal.

JO  - Pharmacoeconomics

PY  - 2013/04/11

AU  - Tosh J

AU  - Archer R

AU  - Davis S

AU  - Stevenson M

AU  - Stevens JW

ED  - 

DO  - DOI: 10.1007/s40273-013-0052-7

VL  - 31

IS  - 8

SP  - 653

EP  - 661

Y2  - 2024/10/18

ER  -